What changed: HER2-mutant non-small-cell lung cancer
Every dated change on the records linked to HER2-mutant non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result4Milestone4This record1
September 2026 · 1
2025 · 3
- 2025Trial resultBeamion LUNG-1Beamion LUNG-1 reported
Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.
- 2025Trial resultSOHO-01SOHO-01 reported
ORR ~64%; accelerated approval Nov 2025.
- 2025MilestoneBeamion LUNG-1Beamion LUNG-1: zongertinib approved, the first oral HER2 inhibitor for lung cancer
A milestone in how this cancer is treated.